Neuronetics earnings release, May 5, 2026

Neuronetics, Inc. (STIM) · Form 8-K, Item 2.02 · Filed · SEC filing

Neuronetics Reports First Quarter 2026 Financial and Operating Results

MALVERN, PA., May 5, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2026.

First Quarter 2026 Highlights

Recent Operational Highlights

“I’m encouraged by our first quarter performance, which reflects the team’s continued execution on revenue growth, operational efficiency, and cash management. Our clinic business delivered double-digit growth, we reduced operating expenses, and we meaningfully improved our operating cash flow versus the first quarter of last year,” said Dan Reuvers, President and Chief Executive Officer of Neuronetics. “Looking ahead, I believe there is significant value in this business that has yet to be fully realized. We have the leading technology in TMS, a national clinic platform with real growth runway, and a team that is driving operational execution. Our team is focused on delivering better outcomes for our customers and patients, as well as long term value for our shareholders.”

First Quarter 2026 Financial and Operating Results for the Three Months Ended March 31, 2026

Total revenue for the three months ended March 31, 2026 was $34.5 million, an increase of $2.5 million, or 8%, compared to the three months ended March 31, 2025 revenue of $32.0 million. The increase in revenue was primarily driven by higher U.S. clinic revenue, which increased to $21.5 million in the first quarter of 2026 from

$18.7 million in the first quarter of 2025, reflecting strong growth since the Greenbrook acquisition and continued expansion of SPRAVATO®, including the buy and bill model.

U.S. NeuroStar Advanced Therapy System revenue for the three months ended March 31, 2026 was $3.2 million, an increase of 13% compared to $2.8 million in the first quarter of 2025. For the three months ended March 31, 2026, the Company shipped 34 systems.

U.S. treatment session revenue was $9.1 million for the three months ended March 31, 2026, a decrease from $9.6 million for the three months ended March 31, 2025.

U.S. clinic revenue was $21.5 million for the three months ended March 31, 2026, compared to $18.7 million for the three months ended March 31, 2025, representing an increase of 15%.

Gross margin for the first quarter of 2026 was 46.9% compared to the first quarter of 2025 gross margin of 49.2%. The decrease in gross margin was primarily a result of mix.

Operating expenses during the first quarter of 2026 were $25.1 million, a decrease of $1.6 million, or 6%, compared to $26.8 million in the first quarter of 2025, mainly attributable to savings in general, administrative, sales and marketing expenses.

Net loss for the first quarter of 2026 was $(10.8) million, or $(0.16) per share, as compared to $(12.7) million, or $(0.21) per share, in the first quarter of 2025. Net loss per share was based on 69,589,144 and 61,464,725 weighted average common shares outstanding for the first quarters of 2026 and 2025, respectively.

As of March 31, 2026, the Company held $19.0 million in total cash, consisting of cash and cash equivalents of $13.2 million and

$5.8 million of restricted cash, which is compared to $34.1 million as of December 31, 2025. As previously announced, the Company made a one-time principal payment of $5.0 million in March to reduce its debt obligation and ongoing interest expense.

Optum/UHC/UBH expanded its TMS clinical policy to allow Nurse Practitioners to order, supervise, and administer NeuroStar Advanced Therapy

Optum/United Healthcare/United Behavioral Health (“Optum/UHC/UBH”) has expanded its transcranial magnetic stimulation (“TMS”) clinical policy to allow psychiatric mental health nurse practitioners (“PMHNPs”) to order, supervise, and administer NeuroStar Advanced Therapy, significantly broadening access to this non-drug, non-invasive treatment for major depressive disorder (“MDD”). Previously limited to psychiatrists, the updated policy applies to PMHNPs practicing in states with full practice authority and extends access across 26 states and Washington, D.C., reaching approximately 34.8 million covered lives. This milestone policy change is expected to enhance patient access—particularly in underserved communities—by enabling more qualified providers to deliver NeuroStar TMS Therapy, a clinically proven option for patients who have not achieved adequate relief from antidepressant medications.

Business Outlook

For the second quarter of 2026, the

Company expects total revenue growth in the mid-single digits.

For the full year 2026, Neuronetics continues to expect:

Webcast and Conference Call Information

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/3pztkve5.

To listen to the conference call on your telephone, you may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers,... (truncated)nc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading

TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO®

(esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged

15-21.

For safety information and indications for use, visit

NeuroStar.com.

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:

Financial statements

Income Statement

Revenues by Geography Three Months Ended March 31, — First Quarter 2026 Financial and Operating Results for the Three Months Ended March 31, 2026 (Unaudited; in thousands, except percentages)

Revenues by Geography Three Months Ended March 31, – 2026 – Amount – (Unaudited; in thousands, except percentages)Revenues by Geography Three Months Ended March 31, – 2025 – Amount – (Unaudited; in thousands, except percentages)% Change – (Unaudited; in thousands, except percentages)
U.S.34,22631,4839.0%
International228492-54.0%
Total revenues34,45431,9758.0%

Income Statement

Three Months ended — (Unaudited; In thousands, except per share data)

Three Months ended – March 31, – 2026Three Months ended – March 31, – 2025
RevenuesProducts and other12,92513,316
RevenuesServices21,52918,659
RevenuesTotal Revenue34,45431,975
Cost of revenuesProducts and other2,8583,150
Cost of revenuesServices15,44213,087
Cost of revenuesTotal Cost of revenues18,30016,237
Cost of revenuesGross profit16,15415,738
Operating expenses:Sales and marketing10,73711,999
Operating expenses:General and administrative13,04813,137
Operating expenses:Research and development1,3641,616
Operating expenses:Total operating expenses25,14926,752
Operating expenses:Loss from operations-8,995-11,014
Other (income) expense:Interest expense2,2661,922
Other (income) expense:Loss on extinguishment of debt539
Other (income) expense:Other income, net-1,020-247
Other (income) expense:Net loss-10,780-12,689
Other (income) expense:Less: Net gain (loss) attributable to non-controlling interest10-14
Other (income) expense:Net loss attributable to Neuronetics stockholders’-10,790-12,675
Other (income) expense:Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders-0.16-0.21
Other (income) expense:Weighted average common shares outstanding, basic and diluted69,58961,465

Income Statement

Three Months ended March 31, — The following table reconciles reported net loss to EBITDA and Adjusted EBITDA: (in thousands)

Three Months ended March 31, – 2026Three Months ended March 31, – 2025
Net loss attributable to Neuronetics stockholders’-10,790-12,675
Interest expense, net1,2461,675
Depreciation and amortization745911
EBITDA-8,799-10,089
Stock based compensation (Note. 1)1,6771,444
Loss on extinguishment of debt (Note.2)539
Adjusted EBITDA-6,583-8,645

Balance Sheet

December 31, — (Unaudited; In thousands, except per share data)

March 31, – 2026December 31, – 2025
Current assets:Cash and cash equivalents13,21428,134
Current assets:Restricted cash5,7506,000
Current assets:Accounts receivable, net of allowance for credit losses of $780 and $1,043 as of March 31, 2026 and December 31, 2025, respectively15,80916,469
Current assets:Inventory4,7154,327
Current assets:Current portion of net investments in sales-type leases257225
Current assets:Current portion of prepaid commission expense2,9003,050
Current assets:Current portion of note receivables401424
Current assets:Prepaid expenses and other current assets4,1292,922
Current assets:Total current assets47,17561,551
Current assets:Property and equipment, net3,8744,466
Current assets:Goodwill23,62223,622
Current assets:Intangible assets, net17,78518,149
Current assets:Operating lease right-of-use assets23,06923,560
Current assets:Net investments in sales-type leases10898
Current assets:Prepaid commission expense7,4647,972
Current assets:Long-term notes receivable92151
Current assets:Other assets2,2511,982
Current assets:Total assets125,440141,551
Current liabilities:Accounts payable11,43310,739
Current liabilities:Accrued expenses9,59612,316
Current liabilities:Current portion of deferred revenue833753
Current liabilities:Deferred and contingent consideration250500
Current liabilities:Other payables751652
Current liabilities:Current portion of operating lease liabilities5,4225,561
Current liabilities:Total current liabilities28,28530,521
Current liabilities:Long-term debt, net61,29765,807
Current liabilities:Other long term liabilities71
Current liabilities:Deferred revenue5848
Current liabilities:Operating lease liabilities18,66918,935
Current liabilities:Total liabilities108,380115,311
Equity:Common stock, $0.01 par value: 250,000 shares authorized; 69,583 and 68,994 shares issued and outstanding on March 31, 2026 and December 31, 2025, respectively696690
Equity:Additional paid-in capital482,146480,475
Equity:Accumulated deficit-469,577-458,787
Equity:Total Stockholders’ equity13,26522,378
Equity:Non-controlling interest3,7953,862
Equity:Total equity17,06026,240
Equity:Total liabilities and equity125,440141,551

Cash Flow

Three months ended March 31, — (Unaudited; In thousands) (in thousands)

Three months ended March 31, – 2026Three months ended March 31, – 2025
Cash flows from operating activities:Net loss-10,780-12,689
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization745911
Adjustments to reconcile net loss to net cash used in operating activities:Allowance for credit losses-267
Adjustments to reconcile net loss to net cash used in operating activities:Inventory impairment-305
Adjustments to reconcile net loss to net cash used in operating activities:Share-based compensation1,6771,444
Full release

Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,”

“plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”

“predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal year 2026, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability and existing cash balance; and our ability to achieve positive cash flows. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form

10-K for the fiscal year ended

December 31, 2025 and the company’s Quarterly Report on Form

10-Q for the quarter ending March 31, 2026, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.

Investor Contact:

Mike Vallie or Mark Klausner

ICR Healthcare

443-213-0499 ir@neuronetics.com

Media Contact:

EvolveMKD

646-517-4220

NeuroStar@evolvemkd.com

NEURONETICS, INC.

Consolidated Statements of Operations

(Unaudited; In thousands, except per share data)

NEURONETICS, INC.

Consolidated Balance Sheets

(Unaudited; In thousands, except per share data)

NEURONETICS, INC.

Consolidated Statements of Cash Flows

(Unaudited; In thousands)

Non-GAAP

Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA are not measures of financial performance under generally accepted accounting principles in the U.S. (“GAAP”), and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s... (truncated)nd its business. Further, management believes that the addition of the non-GAAP financial measures provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment.

The following table reconciles reported net loss to

EBITDA and Adjusted EBITDA:

Footnotes

References

1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Neuronetics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.